Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 8, 2021

View Archived Issues

Sanofi selects NK cell engager IPH-6101 as drug candidate

ApoE multitasks for regulating brain lipids

Extension study results of patisiran in transthyretin-related amyloid polyneuropathy presented

HDGF is a therapeutic target in hepatitis

FDA clears IND for phase I trial of PRGN-2012 for recurrent respiratory papillomatosis

Vir initiates phase I trial of HIV T-cell vaccine VIR-1111

Activating NK cells without interleukins

Dosing initiates in phase IIa study of MET-409 plus empagliflozin in patients with T2DM and NASH

First patient dosed in phase I study of Replimune's third clinical candidate, RP-3

Topline data presented from phase III KEEPsAKE studies of risankizumab

HELIOS-A phase III study of vutrisiran meets its primary and secondary endpoints

FDA approves IND for phase IIb study of orismilast in patients with plaque psoriasis

REGENXBIO announces development updates for RGX-314 and RGX-202

Beijing Reciproca Pharmaceuticals patents new CDK inhibitors

Chinese researchers presents new SERCAs for breast cancer

GlaxoSmithKline plc discloses new antibacterials

LY-CoV555 does not show efficacy in hospitalized patients with COVID-19

Pfizer and CTxT Pty synthesize KAT inhibitors

Penciling in the right base corrects progeria mutation

ViiV Healthcare discovers compounds for HIV infection

Phase III induction studies of risankizumab in Crohn's disease meet primary endpoints

AstraZeneca's COVID-19 vaccine receives further emergency use authorizations

Aldeyra reports topline phase III data on reproxalap in dry eye disease

REMD reports phase II topline data on volagidemab in type 1 diabetes

Phase III RISE trial of TV-46000 in schizophrenia meets primary endpoint

NorthSea reports interim phase IIb data on icosabutate in NASH

Part 1 topline data reported from trial of SRP-9001 in Duchenne muscular dystrophy